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LangendorffDespite promising results in clinical trials conducted to date, little is known about how cardiac contractile
modulation (CCM) mediated inotropic enhancement occurs and how CCM affects the electrophysiological
characteristics of the heart. The aims of the present study were to 1) investigate how the stimulation
parameters of the CCM signal and the location of stimulus delivery inﬂuence the contractile response,
2) characterise the effect of CCM on ventricular electrophysiology, and 3) investigate the potential
physiological mechanisms underlying these acute inotropic and electrophysiological effects. Experiments
were conducted in isolated rabbit hearts with simultaneous measurement of ventricular contractility and
monophasic action potential duration (MAPD). Biphasic square wave pulses were applied to the left ventricle,
timed to coincide with the absolute refractory period. CCMmediated responses were assessed over a range of
signal amplitudes (2–30 mA), durations (2–15 ms) and delays from the activation of the locally recorded
monophasic action potential (0–30 ms). Responses were assessed during perfusion with the β1-adrenoceptor
antagonistmetoprolol (1.8 μM)andHMR1556 (500 nM), an inhibitor of the slowdelayed rectifying potassium
current. Norepinephrine content was collected and assessed by ELISA from samples of coronary efﬂuent
collected during CCM. CCM induced a signiﬁcant increase in left ventricular pressure (LVP) in a manner
dependent upon the amplitude and duration of the CCM signal but independent of the delay of the stimulus
within the action potential plateau andwas associated with an increase in norepinephrine in coronary efﬂuent
(Mean: 46±9 pg/ml). CCM promoted a shortening of MAPD-90% close to the site of stimulation (−19±3%)
but had no effect on those recorded at distant sites (0±1%). The increase in LVP (4.7±1.8 vs. 0.7±0.9%,
Pb0.01) and shortening of local MAPD-90% (−15±3 vs. 1±1%, Pb0.01) was abolished with metoprolol.
Perfusion with HMR 1556 caused a signiﬁcant inhibition of local MAPD shortening (−27±2 vs.−21±3 ms,
Pb0.05). CCM is associated with a shortening of ventricular MAPD in a manner dependent upon β-
adrenoceptor stimulation resulting from catecholamine release, a ﬁndingwhichmay be of clinical signiﬁcance
in regard to the development ofmalignant ventricular arrhythmias. This article is part of a Special Issue entitled
Possible Editorial.vascular Sciences, Cardiology
, Glenﬁeld Hospital, Leicester,
7 5792.
-NC-ND license.© 2011 Elsevier Ltd.Open access under CC BY-NC-ND license.1. Introduction
Application of electrical currents to the myocardium during the
absolute refractory period of the ventricular action potential enhances
ventricular inotropy in vivo and in a wide range of isolated cardiac
tissue preparations [1–4]. This effect, termed cardiac contractility
modulation (CCM) is a novel therapeutic treatment for use in patients
with heart failure who are unresponsive to conventional drug
therapies and/or ineligible for/unresponsive to cardiac resynchronisa-tion therapy. Despite several studies on CCM, little is known about the
mechanisms by which this form of non-excitatory stimulation
enhances ventricular contractility.
It is possible that electrical stimulation of the myocardium could
stimulate autonomic nerves within the myocardium and thereby
promote the release of adrenergic neurotransmitters from sympa-
thetic nerve terminals. However, experimental evidence to date has
been conﬂicting. Early reports in isolated rabbit papillary muscles
demonstrated that inotropic response to CCM was unchanged during
pharmacological β-adrenoceptor blockade [4]. Similarly the inotropic
effects of CCMwere not blocked in isolated ferret hearts perfusedwith
the β adrenoceptor antagonist propranolol [3], although there was a
trend for towards a reduction in left ventricular inotropy and systolic
level of the Ca2+ transient. More recently, Meyer et al. reported that
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absolute refractory period (similar to CCM) in sheep promoted an
increase in ventricular pressure development that was abolished
when these animals were pre-treated with propranolol [5], providing
indirect evidence that application of electrical signals to the heart
during the refractory period could stimulate the release of sympa-
thetic neurotransmitters.
In addition to an increase in contractility, early studies in isolated
papillary muscles [4] suggested that CCM prolongs action potential
duration and indicated a potential direct effect of CCMon sarcolemmal
ion channels (e.g. the L-type Ca2+ channel). To our knowledge these
ﬁndings have yet to be conﬁrmed in the whole heart. As the activation
and recovery of speciﬁc depolarising and repolarising currents change
over the cardiac cycle, it is important to assess whether differences in
the parameters of the CCM signal would inﬂuence the inotropic and
electrophysiological response to CCM. This is supported by the lack of
such data within the literature. In addition, knowledge of the effect of
CCM signal parameters on the response may be of clinical importance
to establish clinical efﬁcacy. The role of adrenergic neurotransmitter
release and concurrent β-adrenoceptor activation in the acute
mechanisms of CCM induced inotropy require further investigation
as do the electrophysiological effects of CCM in the whole heart.
The aims of the present study are to1) investigate how the stimu-
lation parameters of the CCM signal and the location of stimulus
delivery inﬂuence the contractile response in, 2) characterise the effect
of CCM on ventricular electrophysiology, and 3) investigate the
potential physiological mechanisms underlying these acute inotropic
and electrophysiological effects in isolated rabbit hearts.2. Materials and methods
2.1. Animal welfare
All procedures were undertaken in accordance with ethical
guidelines set out by the UK Animals (Scientiﬁc Procedures) Act 1986
and conformed to the Guide for the Care and Use of Laboratory Animals
Published by the US National Institutes of Health (NIH Publication
No.85-23, revised 1985).Fig. 1. CCM signal. A square wave bipolar signal is applied directly to the surface of the
LV during the absolute refractory period. Signal delay is timed from the point of
activation of a locally recorded mono-phasic action potential.2.2. Langendorff tissue isolation and perfusion
Adult male New Zealand White rabbits (2.0–2.5 kg, n=21) were
pre-medicated with ketamine (Ketaset, 10 mg/kg, Fort Dodge,
Southampton, UK), medetomidine hydrochloride (Sedator, 0.2 mg/kg,
Dechra, Shrewsbury, UK) and butorphanol (Torbugesic, 0.05 mg/kg,
Fort Dodge Southhampton, UK) (i.m.). 15–20 min later, animals were
sacriﬁced with an overdose of pentobarbitone sodium (Sagatal, Rhone
Merieux, Harlow, UK; 0.8 mg/kg. body weight, i.v.) containing Heparin
(1000 IU, Multiparin, Wrexham, United Kingdom) via the marginal ear
vein. Theheartswere rapidly excised and retrogradely perfused through
the ascending aorta (40 ml/min) using a Gilson Minipulse 3 peristaltic
pump (Anachem, Luton, UK). The heart was perfused with Tyrode
solution of the following composition (mM): Na+ 138.0, K+ 4.0, Ca2+
1.8,Mg+1.0, HCO3− 24.0, H2PO4− 0.4, Cl− 121.0, glucose 11.0 and acetate
20.0. The solution was continuously bubbled with 95% O2–5% CO2 to
maintain a constant pH of 7.4. Temperature was maintained at 37 °C. A
3F polypropylene catheter (Portex, Kent, United Kingdom)was inserted
at the apex of the left ventricle (LV) for drainage of Thebesian venous
efﬂuent. Intra-ventricular left ventricular pressure (LVP)wasmonitored
with a ﬂuid-ﬁlled latex balloon connected to a pressure transducer
(MTL0380, ADInstruments Ltd, Chalgrove, UK) and inserted into the LV
via the left atrium. Left ventricular end diastolic pressure was adjusted
to zero. Aortic perfusion pressure (AP) was monitored with a second
pressure transducer connected in a series with the aortic cannula.2.3. Cardiac electrical recording and pacing
A pair of platinum electrodes (Grass Instruments, Astro-Medical
Inc., Slough, UK) were inserted into the right atrial appendage for
recording of atrial electrograms. Contact electrodes were used to
record monophasic action potentials (MAPs) from the epicardial
surface of the LV using a DC-coupled high input impedance differential
ampliﬁer (Joint Biomedical Workshop, University of Leicester, UK).
MAPswere recorded from the left ventricular freewall close to (within
5 mm) and distant from the site of stimuli delivery at either apex or
base depending on the experimental protocol. All heartswere paced at
200 bpm via another contact electrode inserted into the right
ventricular apex.
2.4. CCM signal generation and delivery
Square wave electrical pulses were generated using a Neurolog
modular system (Digitimer, Welwyn Garden City, UK) and signal
strength was ampliﬁed through a constant current stimulator (Model
A385, World Precision Instruments, Stevenage, UK). The CCM signal
was applied directly to the epicardial surface of the left ventricular
myocardium through a pair of platinum hook electrodes (Grass
Instruments, Astro-Medical Inc., Slough, UK) as biphasic pulses with
equal positive and negative phase amplitudes. Stimulus amplitude,
duration and delay from activation of MAP (Fig. 1) were varied
according to experimental protocols (see below). CCM signal was
delivered over a period of 2–3 min, allowing for at least a 30-s period of
steady state response, with a 10-min rest period between sequential
stimulations.
2.5. Protocols
2.5.1. Stimulus location
The effect of different stimulus locations was studied to obtain the
optimal location for CCM signal delivery, denoted by the maximal
inotropic response to a stimulation of predeﬁned parameters. Signal
parameters were chosen based on preliminary experiments—signal
amplitude: 20 mA, signal duration: 20 ms (10 ms per phase), delay:
+10 ms following the activation of locally recordedMAP. Stimuliwere
separately applied to the apex, midlevel and base regions of the LV
(Apex–Base=25–30 mm). MAPsweremeasured at the apex and base
of the LV simultaneously.
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In this protocol CCM signals were delivered solely to basal regions
(electrode spacing: 5 mm). All 3 following parameters were examined
in the same hearts (n=6).
2.5.2.1. Stimulus amplitude. Signal duration=10 ms per phase, Signal
delay=+10 ms, Signal amplitude was varied between 4 and 30 mA
during sequential stimulations.
2.5.2.2. Stimulus duration. Signal amplitude=20 mA, Signal delay=
+10 ms. Signal duration was varied between 4 and 30 ms (2 and
15 ms per phase respectively).
2.5.2.3. Stimulus delay. Signal amplitude=20 mA, signal dura-
tion=10 ms per phase. Signal delay was timed to coincide with the
activation of locally recordedMAPs (delay of 0 ms=time of activation).
Signal delay was increased in 10 ms steps, in sequential stimulations,
from 0 to 40 ms.
2.5.3. Mechanisms of CCM
Signal amplitude=20 mA, signal duration=10 ms per phase,
Signal delay=+10 ms. The CCM response was optimised from data
obtained from the experiments described above.
2.5.3.1. Role of β-adrenoceptor activation. Responses were compared
before and during perfusion with the β1-adrenoceptor antagonist
metoprolol (1.8 μM, Sigma-Aldrich, Gillingham, UK).
2.5.3.2. Release of noradrenaline. Samples of coronary efﬂuent (1 ml)
were collected before, during and after CCM at both low (5 mA) and
high (20 mA) amplitudes of CCM stimulation. Noradrenaline content in
these samples was measured directly using a competitive enzyme
linked immunosorbance assay (ELISA) (BA E-5200, Grifﬁn Life Sciences,
Abingdon, UK).
2.5.3.3. Mechanism of CCM activated MAPD shortening. The slow
delayed rectiﬁer potassium current is known to be involved in
β-adrenoceptor induced shortening of action potential duration [6–10].
In the current study, alterations inmonophasic actionpotential duration
(MAPD)were examined during perfusionwith a speciﬁc inhibitor of IKs,Fig. 2. Effect of CCM signal delivery on left ventricular contractility and electrophysiolog
ventricular pressure (LVP) and peak LVP. Right panel. Averaged LVP proﬁles taken from Lef
corresponding monophasic action potentials at baseline (black) and during steady state CCM
(n=1).[(3R,4S)-(+)-N-[3-hydroxy-2,2-dimethyl-6-(4,4,4-triﬂuorobutoxy)
chroman-4-yl]-N-methylmethanesulfonamide (HMR1556 500nM,
Sanoﬁ-Aventis, Frankfurt, Germany). The efﬁcacy of HMR 1556 was
conﬁrmed during perfusion with the non-selective β-adrenoceptor
agonist isoprenaline (ISO), at a dose (5 nM) that produces a similar
degree of inotropy and MAPD shortening to that noted during CCM.
Responses to ISO and CCM (signal amplitude=20mA, signal dura-
tion=10ms per phase, Signal delay=+10 ms)were compared before
and after perfusion of HMR 1556. All hearts were paced at a rate of
250 bpm to circumvent the chronotropic effects of ISO on the sino-atrial
node.
2.6. Signal measurements and analysis
All signalswere recordedwith a PowerLab 8s systemand digitised at
2 kHz using Chart and Scope software (ADInstruments Ltd). Left
ventricular contractile performance was assessed from an average of
20 beats during baseline and during the steady response plateau. MAPD
was measured at 90% repolarisation (MAPD90) averaged over 20 beats
recorded during steady state before and immediately after the cessation
of CCM stimulation. This was necessary due to signal interference from
the CCM signal preventing measurement of MAPs during CCM signal
application.MAPD90 calculationswere performed using customwritten
analysis software (NewMap, Dr. F. Burton, University of Glasgow, UK).
2.7. Statistics
Statistical comparisonsweremade using Student paired t tests, one
or two way ANOVA where appropriate with Bonferroni post hoc test.
All data are presented as mean values±SEM. Pb0.05 was considered
signiﬁcant.
3. Results
3.1. Inotropic and electrophysiological response to CCM
Fig. 2 illustrates the effect of CCM on perfusion pressure, left
ventricular pressure, rate of pressure production and relaxation, and left
ventricular epicardial monophasic action potentials in a typical
experiment. Localised application of electrical signals to the epicardiumy. Left panel. Raw data illustrating the effect of CCM on perfusion pressure (AP), left
t panel, illustrating the rate of pressure development and relaxation together with the
(red). Stimulation parameters: Duration=10 ms, Delay=10 ms, Amplitude=20 mA.
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LVP) and rates of pressure development (dP/dtmax). The increase in peak
LVP occurred within 2 to 5 s after application of the CCM signal and
increased to an initial peak before decreasing to a new steady state that
was higher than baseline. Following cessation of CCM, peak LVP
gradually returned to baseline values within 2 to 3 min. There was
no signiﬁcant effect from CCM on the rate of ventricular relaxation
(dP/dtmin, baseline=−976±95 mm Hg/s) or on perfusion pressure
(AP, baseline=63±5 mm Hg). Left ventricular end diastolic pressure
was similarly unaffected during CCM (baseline=5±1mm Hg). CCM
resulted in a shortening of monophasic action potential, compared
immediately before and immediately after CCM, which recovered to
baseline values 2–3 min following the cessation of stimulation.
3.2. Effect of stimulus location on the response to CCM
Mean data illustrating the percentage change in peak LVP, dP/dtmax
andMAPD90, recorded frommultiple sites simultaneously, are shown in
Fig. 3. CCM signals applied to basal (75±6 vs. 78±6mm Hg, Pb0.01)
and midlevel (74±5 vs. 77±5 mm Hg, Pb0.01) regions promoted
signiﬁcant increases in peak LVP. dP/dtmax was similarly signiﬁcantly
enhanced during CCM stimulation at basal (1205±129 vs. 1355±
148 mm Hg/s, Pb0.01) and midlevel (1200±104 vs. 1351±126 mm
Hg/s, Pb0.01) regions. CCM in apical regions was not associated with
any signiﬁcant change in ventricular inotropy. MAPD90 shortening wasFig. 3. Heterogeneity of CCM response across the heart. Data illustrating the percentage cha
increase (dP/dtmax, Panel B) and apical and basal monophasic action potential duration (MA
M=Midlevel, B=Base. (n=6) Heterogeneity of response to regional stimulation: *Pb0.0
##Pb0.01.evident at regions close to the site of stimulation. During application
of CCM at basal regions there was signiﬁcant−21±4 ms (108±6 vs.
88±7 ms, Pb0.01) decrease in locally recordedMAPD90 and no change
demonstrated in distantMAPD90 recorded fromthe left ventricular apex
(106±6 vs. 106±6 ms). Stimulation in apical regions resulted in a
signiﬁcant −16±5ms (110±4 vs. 91±4 ms, Pb0.05) reduction in
locally recorded MAPD90 and no signiﬁcant change in basal MAPD90
(110±4 vs. 111±3 ms). Midlevel stimulation promoted a signiﬁcant
reduction in basal (−12±5 ms) but not apical MAPD90. There was no
difference in the degree of shortening of locally recorded MAPD90
between apical and basal stimulations (−21±4 vs. −16±5 ms,
P=NS).3.3. Effect of varying the stimulus parameters on the response to CCM
3.3.1. Amplitude
The effect of CCM signal amplitude on peak LVP, dP/dtmax and
MAPD90 from 6 hearts is shown in Fig. 4. Signiﬁcant increases in peak
LVP were noted at stimulus amplitudes of 15 (3.4±0.9 mm Hg,
Pb0.01), 20 (3.9±1.2 mmHg, Pb0.001) and 30 mA (3.7±0.9 mmHg,
Pb0.001). Similarly dP/dtmax was enhanced at stimulus amplitudes of
15 mAor greater. The percentage change in peak LVP and dP/dtmaxwas
related to the stimulus amplitude in a monotonic manner, increasing
to a plateau at stimulus amplitudesN15 mA.nge in peak left ventricular pressure (LVP, Panel A), maximal rate of change of pressure
PD90, Panel C) during CCM at different epicardial sites. Sites of stimulation; A=Apex,
5, **Pb0.01, ***Pb0.001. Proximal vs. distal MAP (see text for discussion): #Pb0.05,
Fig. 4. Effect of varying signal amplitude on the ventricular responses to CCM. Data illustrating the effect of varying the duration of the CCM signal on peak left ventricular pressure
(LVP, Panels A & B), rate of pressure development (dP/dtmax, Panels C & D) and mono-phasic action potential duration (MAPD90, Panel E & F) (n=6). CCM vs. Baseline; *Pb0.05,
**Pb0.01,***Pb0.001.
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stimulus amplitudes of 15 (−28±7 ms, Pb0.01), 20 (−35±5 ms,
Pb0.001) and 30mA(−37±7 ms, Pb0.001). Amonotonic relationship
was observed between the percentage change in MAPD90 and the
stimulus amplitude, demonstrating a plateau at stimulus amplitudes
above 20 mA.
3.3.2. Duration
The effect of CCM signal duration on peak LVP, dP/dtmax and
MAPD90 from 6 hearts is shown in Fig. 5. A signiﬁcant increase in peakLVP was noted at stimulus durations of 2 (2.0±0.4 mm Hg, Pb0.01),
5 (2.5±0.4 mm Hg, Pb0.001), 10 (3.5±0.6 mm Hg, Pb0.001) and
15 ms (3.3±0.5 mm Hg, Pb0.001). Similarly dP/dtmax was enhanced
at all stimulus durations. The percentage change in peak LVP and
dP/dtmax was related to the stimulus duration in a monotonic manner,
increasing to a plateau at stimulus durations N10 ms.
A signiﬁcant shortening of locally recorded MAPD90 was noted at
stimulus durations of 2 (−18±4 ms, Pb0.01), 5 (−22±4 ms, Pb
0.001), 10 (−29±6ms, Pb0.001)and15 ms (−26±6 ms, Pb0.001).A
monotonic relationship was observed between the percentage change
Fig. 5. Effect of varying signal duration on the ventricular responses to CCM. Data illustrating the effect of varying the duration of the CCM signal on peak left ventricular pressure
(LVP, Panels A and B), rate of pressure development (dP/dtmax, Panels C & D) andmono-phasic action potential duration (MAPD90, Panels E and F) (n=6). CCM vs. Baseline; *Pb0.05,
**Pb0.01, ***Pb0.001.
257J. Winter et al. / Journal of Molecular and Cellular Cardiology 51 (2011) 252–262inMAPD90 and stimulus amplitude, demonstrating a plateau at stimulus
amplitudesN10 ms.
3.3.3. Delay
The effect of time delay fromMAP activation to CCM signal on peak
LVP, dP/dtmax and MAPD90 from 6 hearts is shown in Table 1. A
signiﬁcant increase in peak LVP and dP/dtmax was noted at each delay
investigated (0–30 ms). The increase in peak LVP (3.5±0.5 mm Hg,
Pb0.05) and dP/dtmax (126±14 mm Hg/s, Pb0.05) during CCM was
not signiﬁcantly different at any delay studied. The shortening ofMAPD90 was similarly unrelated to the timing of CCM signals during
the absolute refractory period (−23±3 ms, Pb0.01).
3.4. Mechanisms of CCM induced inotropy and electrophysiological
changes
3.4.1. Role of β-adrenoceptors
To investigate the role of β-adrenoceptor stimulation, we examined
the effects of CCM in the absence and presence of the β1-adrenoceptor
antagonistmetoprolol. Raw andmean data illustrating the effect of CCM
Table 1
Effect of varying CCM signal delay on the ventricular responses to CCM.
Peak LVP (mm Hg) dP/dtmax (mm Hg/s) MAPD90 (ms)
Signal delay (ms) Baseline Steady state % Change Baseline Steady state % Change Baseline Steady state % Change
0 74±6 77±6* 5±2 1156±125 1291±151* 12±1 112±6 91±2* −18±5
10 73±5 76±5* 5±1 1153±116 1263±140* 9±2 113±6 87±2** −21±5
20 75±7 79±7* 6±3 1163±148 1297±177* 11±1 115±3 87±5** −23±5
30 75±5 79±6* 5±1 1212±139 1341±165* 10±2 114±5 91±2** −19±4
Data illustrating the effect of varying the delay of the CCM signal on peak left ventricular pressure (LVP), rate of pressure development (dP/dtmax) and mono-phasic action potential
duration (MAPD90) (n=6). CCM vs. Baseline:*Pb0.05, **Pb0.01.
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Perfusion with metoprolol abolished the increase in peak LVP (3.3±1
vs. 0.3±0.4 mm Hg, Pb0.05), dP/dtmax (166±30 vs. 44±4 mm Hg/s,
Pb0.01) and the shortening of locally recorded MAPD90 induced by
CCM (−17±4 vs. 0.2±1.24 ms, Pb0.05).3.4.2. Role of catecholamine release
To establishwhether CCM stimulated noradrenaline releasewas an
underlyingmechanismof action for the effects observed,wemeasured
noradrenaline content in samples of coronary efﬂuent collected
before, during and after CCM. Mean data from 4 hearts illustrating
noradrenaline release and the change in peak LVP frombaseline values
at two stimulation amplitudes are illustrated in Fig. 7. CCM at both low
(5 mA) and high (20 mA) amplitudes resulted in the detection of
noradrenaline increase in the coronary efﬂuent. Noradrenaline
content returned to baseline values following the cessation of stimu-
lation. Signiﬁcantly more noradrenaline was measured during stim-
ulation at high stimulus amplitude when compared to low stimulus
amplitude (46±9 vs.17±5 pg/ml, Pb0.05). The mean steady stateFig. 6. Role of β1-adrenoceptor stimulation in the ventricular response to CCM. Raw data illus
using metoprolol (1.8 μM, Panel B) on left ventricular pressure (LVP), peak LVP and aortic
MAPD90 (Panels C and D) (n=6). The effects of metoprolol: *Pb0.05.increase in peak LVP was greater during high than low stimulus
amplitudes (7.2±1.7 vs. 2.9±0.7 mm Hg, Pb0.05).3.4.3. Mechanism of MAPD shortening
To investigate if MAPD shortening was mediated via the slow
activating delayed rectiﬁer channel IKs, the effects of CCMwere studied
during perfusion with HMR 1556 (500 nM), an inhibitor of IKs and
compared with the effects of perfusion with isoprenaline (ISO). Mean
data from 6 hearts illustrating the effects of HMR 1556 on the
shortening of MAPD induced by CCM and ISO are shown in Fig. 8. ISO
caused a signiﬁcant 5.1±1.6 mm Hg increase in peak LVP (Pb0.05)
and a−27±3 ms reduction in basalMAPD90 at baseline (Pb0.001). In
the presence of HMR1556, the effects of ISO onMAPDwere reduced by
58±4% (−27±3 vs. −11±1 ms, Pb0.05). The change in peak LVP
associated with ISO was unaffected by HMR 1556. The shortening of
MAPD90 associated with CCM was reduced by 26±9% (−33±2 vs.
−25±4 ms, Pb0.05) in the presence of HMR 1556. HMR 1556 had no
effect on the increase in peak LVP associated with CCM (3.4±0.9 vs.
2.9±0.9 mm Hg, P=NS).trating the effect of CCM during control (Panel A) and during β1-adrenoceptor blockade
perfusion pressure (AP). Mean data representing the effect of CCM on peak LVP and
Fig. 7. Role of catecholamine release in the ventricular response to CCM. Mean data
showing the effect of low (5 mA) and high (20 mA) amplitude CCM signals on the
noradrenaline content in samples of coronary efﬂuent (Panel A) and the change in peak
left ventricular pressure (LVP) from baseline values (Panel B). The time course of CCM is
demonstrated by the grey box (0–180 s). The sample at 180 s was collected prior to the
cessation of CCM (n=4).
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To be best of our knowledge, this is the ﬁrst demonstration that the
acute changes in inotropy induced by CCM are associated with a
shortening of ventricular MAPD. In addition, we have shown that the
inotropic and electrophysiological responses to CCM are dependent
upon the location, amplitude and duration of stimulus delivery and
independent of the timing of the stimulus within the refractory period
(delay). Perfusion with metoprolol abolished the effects of CCM
demonstrating a clear dependence upon the activation of myocardial
β1-adrenoceptors. The increase in noradrenaline in the coronary
efﬂuent during CCM indicates that activation of β-adrenoceptors
occurs as a result of the release of sympathetic neurotransmitters.
Finally, we have demonstrated that the CCM signal alters proximal and
not distal action potential duration an effect that is, in part, dependent
on activation of IKs.
4.1. Stimulus parameter dependence of CCM
In the current study, the response to CCM was investigated over a
range of signal parameters and demonstrated that the degree of
contractile force enhancement is dependent upon the anatomical
location of signal delivery, the stimulus amplitude and the duration of
the stimulus but unrelated to the timing of the signal within the action
potential (i.e. the delay). Theﬁnding that CCMefﬁcacy is dependent on
stimulus amplitude and signal duration is supported by studies inisolated rabbit papillary muscles [4] and during stimulation of the
coronary sinus in sheep (amplitude only) [5]. It is conceivable that an
increase in signal amplitude increases the area of the myocardium
which is affected by the signal (i.e. greater current spread) and thus
promotes a greater increase in global contractile force (a spatial effect).
Increases in signal duration result in a greater period of stimulation
and enhanced ventricular inotropy up to a plateau (a temporal effect).
The plateau of the duration–ventricular inotropy relationship dem-
onstrates the existence of a maximal response within a given spatial
region. The role of stimulated noradrenaline release in these relation-
ships is considered later in this discussion.
In our study, the inotropic response to CCM was not dependent on
the timing of the stimulus within the action potential plateau. This
suggests that,while the timing of the CCMsignalmust occurwithin the
absolute refractory period to avoid triggering an additional ventricular
contraction, there is a stable window of opportunity in which CCM
signals can be applied. The previously reported linear dependence
between contractile enhancement and signal delay in isolated rabbit
papillarymuscles [4] is at oddswith the current study. Thismay reﬂect
differences in the experimental preparation utilised (i.e. isolated
muscle strip vs. whole organ responses) and/or highlight the multi-
factorial mechanisms of CCM induced inotropic enhancement.
4.2. Intracardiac noradrenaline release and CCM
We have shown that the acute effects of CCM are abolished in the
presence of the β1-adrenoceptor antagonist metoprolol and that CCM
is associated with an increase in noradrenaline in samples of coronary
efﬂuent in a manner correlated with the magnitude of inotropic
enhancement. It is therefore clear that noradrenaline release and
concurrent activation ofβ1-adrenoceptors underlies the increase in LV
inotropy and alterations in electrophysiology acutely associated with
CCM in the rabbit heart. Our data are supported by the ﬁndings of
Meyer et al. who found that the inotropic enhancement associated
with refractory stimulation of the coronary sinus in sheep was
completely abolished during β-adrenoceptor blockade [5]. Mohri et
al. also reported a modest, but incomplete, inhibition of the inotropic
response to CCMduringperfusionwith propranolol [3]. In contrast, the
acute inotropic effects of CCM were preserved in the presence of
propanolol in experiments performed in left and right isolated
ventricular rabbit papillary muscles [4]. Previous investigators have
reported that CCM is associated with an increase in the amplitude of
the Ca2+ transient [3], phosphorylation of phospholamban [11] and
that the inotropic response is dependent upon the entry of Ca2+
through the L-type Ca2+ channels [4]. These ﬁndings correlate with
thewell-described intracellularmechanismswherebyβ-adrenoceptor
stimulation results in myocardium inotropic enhancement [13].
Whilst our study does not provide any speciﬁc details of intracellular
calcium homeostasis during CCM inotropy, it is likely that adrenergic
activation will stimulate the L-type calcium channel, promote calcium
release from the sarcoplasmic reticulum and stimulate an increase in
calcium reuptake into the sarcoplasmic reticulum via SERCA (second-
ary to phospholamban phosphorylation), although the lack of
enhancement of the rate of pressure relaxation in the current study
may refute this point.
The ventricular myocardium is richly innervated with efferent
sympathetic nerve ﬁbres and it is likely that these ﬁbres are stimulated
to release noradrenaline by the delivery of electrical signals to the
epicardial surface. Importantly, several studies have previously shown
that electrical signals, not speciﬁcally timed to the absolute refractory
period, can be used to stimulate catecholamine release from the
perfused whole hearts and from isolated samples of cardiac tissue
[14,15]. The distribution of sympathetic nerve ﬁbres throughout the
ventricle has been shown to be heterogenous with a gradient of ﬁbre
density from basal (highest) to apical (lowest) regions [16,17].We have
previously shown that the expression of tyrosine hydroxylase protein,
Fig. 8. Role of the slow delayed rectifying potassium current in CCM induced shortening of ventricular mono-phasic action potential duration. Raw data illustrating the effect of CCM
(Panel A) and isoprenaline (ISO, 5 nM) (Panel B) on monophasic action potential duration (MAPD) recorded from basal regions (BL=baseline). Mean data showing the effect of
HMR 1556 (500 nM) on the shortening of MAPD induced by CCM (Panel C) and ISO (Panel D). The mean effects of HMR 1556 on the change in peak LVP induced by CCM (Panel E)
and ISO (Panel F) (n=6 CCM, 3 ISO).
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homogenates of rabbit ventricular tissue taken from basal than in those
taken from apical regions [18]. Other studies have demonstrated a
graded distribution of ventricular catecholamine content from the base
to the apex in the canine heart [19] and reported greater proportion of
adrenergic ﬁbres innervating basal regions of the human and canine
ventricular tissue [16,17]. These anatomical/histological ﬁndings pro-
vide a possible explanation for the differential inotropic effects noted
during basal, midlevel and apical stimulation. In addition these data
provide a greater understanding of the previously discussed relation-
ships between signal amplitude (spatial), signal duration (temporal)
and ventricular inotropy. The degree of inotropy likely reﬂects the
proportion of sympathetic ﬁbres stimulated within a given region or
over a given period of time. Increases in signal amplitudewill result in a
greater spread of the electrical ﬁeld and an increase in the current
density (i.e. ﬁeld intensity). As the spread and intensity of the electrical
ﬁeld is increased then a greater proportion of nerveﬁbres are likely tobe
stimulated resulting in a greater release of noradrenaline. This is
reﬂected in our ﬁnding of a greater concentration of noradrenaline in
samples of coronary efﬂuent collectedduringCCMathigh amplitudes. A
further point for consideration is that stimulation within a given regionmay propagate the stimulation of nerves and release of noradrenaline
throughout the ventricle. It is known that the myocardium exhibits a
rich intrinsic innervation and that sympathetic efferent ﬁbres run from
basal to apical regions and innervate both epicardial and endocardial
portionsof themyocardium [20]. It seemsunlikely that alterations in the
signal delay should inﬂuence the contractile responses to CCM if such
changes are mediated by catecholamine release from the sympathetic
innervations of the LV, as our data indicate. Instead, varying CCM signal
delivery is likely to beof critical clinical importance to avoid arrhythmias
induced by inappropriately timed stimuli.
In the present study, CCM induced an increase in ventricular
pressure development and contractility without signiﬁcantly altering
ventricular relaxation. Thesedata are supportedby theﬁndings ofMohri
et al. in the dog who reported no enhancement of either global or
regional ventricular relaxation during CCM delivery to the ventricular
epicardial surface [2]. In contrast, Meyer et al. found enhanced rates of
ventricular relaxation during electrical stimulation in sheep [5]. It seems
probable that this reﬂects the proportion of the myocardium, or more
probably the proportion of sympathetic ﬁbres, stimulated during CCM.
Previous histological studies have identiﬁed a signiﬁcant proportion of
sympathetic ﬁbres which cross the coronary sinus [20]. Therefore
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homogenously distributed release of noradrenalinewithin theventricle.
The proportion of sympathetic ﬁbres stimulated in the present study,
and in that of Mohri et al.[2], may be insufﬁcient to signiﬁcantly alter
global ventricular relaxation. In a recently published study Zhang et al.
reported on the effects of CCM on cardiac function in rabbits with
coronary ligation induced heart failure [21]. Acute CCM enhanced
ventricular inotropy during stimulation at the anterior LV free wall and
to a lesser degree during stimulation at the right ventricular septum.
Ventricular lusitropy was only enhanced during LV free wall stimula-
tion. While no speciﬁc information is presented on the site and size of
region stimulated in this study these data do provide evidence that the
location of signal delivery is an important determinant of the effects of
CCM on ventricular function. The ﬁndings of the present study do not
rule out alterations in regional relaxation which are not reﬂected in
global measures.
4.3. CCM and ventricular electrophysiology
Wehave shown that the duration ofMAPs recordedproximal to the
site of stimulation are signiﬁcantly shortened in a manner dependent
upon the amplitude, duration and location of the stimulus. To the best
of our knowledge this is the ﬁrst report of the electrophysiological
effects directly recorded from sites close to the CCMsignal in thewhole
heart and represents a ﬁnding of potential clinical importance (see
later). In keeping with our theory of the adrenergic dependence of
CCM, we found that the shortening of MAPD was abolished during
perfusion with metoprolol. Conventionally accepted evidence in
isolatedmyocytes [6] and the whole heart [22] indicate that activation
of the β1-adrenoceptors promotes shortening of ventricular action
potential duration. From a mechanistic standpoint we have demon-
strated that the shortening of locally recorded MAPD is partially
dependent on the activation of IKs. IKs forms the slow component of the
delayed rectiﬁer outward potassium current is responsible for the
increased rate of repolarisation associated with adrenergic activa-
tion and is present in a number of animal species including the rabbit
[6–10]. While IKs is reported to have little effect in un-stimulated
conditions, it is activated byβ-adrenoceptor stimulation and promotes
a shortening of ventricular action potential duration (a result of
protein kinase A dependent phosphorylation) [6]. The incom-
plete inhibition of CCM induced MAPD shortening by HMR 1556
suggests that other repolarising currents may be activated during
CCM. β-adrenoceptor stimulation is known to increase the ﬂow of
ionic currents through the L-type Ca2+ channels (ICaL), Na+/Ca2+
exchanger (INCX), IKS and chloride channels (ICl,Ca and ICl-cAMP).
Activation of ICl will increase the outward current of negatively
charged chloride ions and could contribute to the shortening of
ventricular APD during CCM. In addition the activation of Ca2+ uptake
by the sarcoplasmic reticulum ATPase (SERCA) and the enhancement
of Ca2+ release by the ryanodine receptors should produce a Ca2+
transient of greater amplitude but of reduced duration, though our
functional evidence and the previous reports, using aequorin Ca2+
ﬂuorescence in the ferret heart, suggest that the Ca2+ duration is
unaffected by CCM. We also cannot rule out the actions of other co-
released neurotransmitters from adrenergic stimulation other than
noradrenaline.
Previous investigators have suggested that CCM can induce
enhanced calcium entry into the myocytes through direct modiﬁca-
tion of the L-type calcium channels. These early studies in isolated
rabbit papillary muscles suggest that an enhancement of calcium
inﬂux prolongs APD [4]. In contrast, we have found that CCM
induces shortening of ventricular MAPD in a manner dependent
upon β1-adrenocptor stimulation, likely occurring secondary to
catecholamine release from sympathetic nerve ﬁbres. While it cannot
be ruled out that these differences reﬂect the species of animal, the
type of preparation and/or the methods utilised in each study, ourdata provide the ﬁrst evidence of the electrophysiological effects of
CCM in the whole heart. The inotropic and electrophysiological effects
of β-adrenoceptor stimulation (see above) are well described and can
account for a number of the molecular changes noted in previous
studies with CCM (i.e. increased L-type calcium current and phos-
phorylation of phospholamban).
4.4. Clinical implications
Our study indicates that β1-adrenoceptor activation is primarily
responsible for the acute inotropic enhancement and electrophysio-
logical changes associated with CCM. This has obvious clinical
implications since current treatment guidelines indicate the use of
β-adrenoceptor antagonists in the treatment of patients with systolic
heart failure. Interestingly, experimental studies in dogs with micro-
embolism induced heart failure have shown additive beneﬁcial effects
when CCM therapy was combined with β-adrenoceptor antagonism
[11]. Moreover, the results of clinical studies conducted to date show
that CCM therapy used in conjunction with traditional pharmacolog-
ical therapies increases patient exercise capacity improves quality of
life measures and is able to reverse the detrimental molecular and
structural remodelling associated with heart failure [23–25]. It is
unlikely that complete inhibition of the β-adrenoceptors is achieved in
the clinical situation, owing to the adverse side-effects of the high
doses ofβ-adrenoceptor blocking drugs thatwould be required, and so
CCM may still be effective in these patients. It is known that acute
inotropic effects of CCM were still observed in early feasibility studies
conducted in patients with systolic heart failure who were receiving
optimised medical therapy (including β-adrenoceptor antagonists)
[26]. The intermittent nature of CCM therapy, which utilises periods
with and without CCM stimulation, may be akin to exercise therapy
whichhas been shown tohavebeneﬁcial effects inpatientswith varying
degrees of heart failure and who are already receiving β-blockade
therapy [12]. It also cannot be ruled out that the long-term beneﬁtic of
CCM therapy are mediated by other mechanisms than those which
mediate the acute inotropic effects, this could include the release of
other autonomic factors.
Previous attempts to utilise inotropic pharmacological agents in
the treatment of heart failure have been unsuccessful; resulting in a
greater number of patient deaths in the treatment arm of these studies
[27]. However results from large scale clinical trials with CCM therapy
(i.e. FIX-HF4 [23] and the preliminary ﬁndings of FIX-HF5 [24] suggest
that CCM does not alter patient mortality rates at 3–6 months follow
up. It is tempting to hypothesise that the localised stimulation of
catecholamine release avoids the systemic complications and chronic
effects of pharmacological agents, though greater patient numbers and
longer follow-up data are required.
The local speciﬁc electrophysiological effects of CCM raises the
question of whether CCM is pro-arrhythmic as regional variations in
repolarisation could promote the development of re-entrant arrhyth-
mias. In addition,wehavepreviously shown that sympathetic activation
increases the susceptibility to ventricular ﬁbrillation in experimental
conditions [28] and there is clear link between sympathetic drive and an
increase in arrhythmic risk in clinical studies [29,30]. Therefore it seems
plausible that CCM has a potential to increase the risk of ventricular
arrhythmias, althoughpreliminary anecdotal evidencedoes not support
this suggestion. Clinical studies conducted to date suggest that CCM is
not associated with any increase in hospitalisations for arrhythmic
events [23,24], though more robust and rigorous scientiﬁc evidence is
needed to support these short term epidemiological ﬁndings.
5. Conclusions
We have demonstrated that the acute inotropic and electrophys-
iological effects of CCM therapy are associated with the release of
noradrenaline and concurrent stimulation of β1-adrenoceptors. In
262 J. Winter et al. / Journal of Molecular and Cellular Cardiology 51 (2011) 252–262contrast to early reports we found that CCM was associated with a
shortening of ventricular MAPD in amanner partially dependent upon
the activation of IKs, a ﬁnding which may be of clinical importance.
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CCM: Cardiac contractility modulation
LVP: Left ventricular pressure
MAP: Monophasic action potential
MAPD: Monophasic action potential duration
dP/dtmin: Minimum rate of change of pressure
dP/dtmax: Maximum rate of change of pressure
